Lyell Immunopharma, Inc. (LYEL)

Last Closing Price: 0.40 (2025-05-29)

Net Income (Quarterly)

Net Income: Company's net profit or loss after all revenues, income items, and expenses have been accounted for. Because this figure is given after preferred dividend expense, it is the net income value allotted to common shareholders.

Lyell Immunopharma, Inc. (LYEL) had Net Income of $-52.20M for the most recently reported fiscal quarter, ending 2025-03-31.

Figures for fiscal quarter ending 2025-03-31
Income Statement Financials
$0.01M
Net Income
$-52.20M
--
$0.01M
$57.37M
$-57.37M
$5.17M
$-52.20M
$-52.20M
$-52.20M
$-52.20M
$-52.20M
$-52.20M
$-57.37M
$-55.65M
295.10M
295.10M
$-0.18
$-0.18
Balance Sheet Financials
$309.18M
$44.20M
$120.62M
$429.80M
$41.28M
--
$51.99M
$93.28M
$336.52M
$336.52M
$336.52M
295.28M
Cash Flow Statement Financials
$-54.74M
$69.47M
$0.00M
$107.29M
$122.02M
$14.73M
$6.02M
--
--
Fundamental Metrics & Ratios
7.49
--
--
--
--
100.00%
-819528.50%
-819528.50%
--
-745642.80%
-745642.80%
$-54.98M
--
--
--
0.00
--
--
--
-15.51%
-15.51%
-12.14%
-15.51%
$1.14
$-0.19
$-0.19